Dubai recently played host to MAHABIZ 2024, a groundbreaking event orchestrated by SAVA Healthcare Limited (SHL), alongside the Gulf Maharashtra Business Forum (GMBF) Global and Maharashtra Chamber of Commerce, Industry and Agriculture (MACCIA). Aligning with the recent signing of the Comprehensive Economic Partnership Agreement (CEPA) between India and the UAE, the two-day conclave attracted over 700 entrepreneurs and business leaders from India, the Middle East, Southeast Asia, and Africa.
Expanding Horizons:
Mahabiz 2024 served as a platform for fostering collaboration and growth opportunities between the UAE and Maharashtra. Virtually graced by esteemed dignitaries including Union Minister for Road Transport & Highways, Nitin Gadkari, and Chief Minister of Maharashtra, Eknath Shinde, the event saw Her Royal Highness Sheikha Jawaher Bint Khalifa Al Khalifa as the Chief Guest. Gadkari spotlighted India’s strides in sustainability, emphasizing renewable energy and the nation’s commitment to carbon neutrality by 2070.
Unlocking Potential:
Vinod Jadhav, Chairman of SAVA Healthcare Limited, underscored Dubai’s strategic importance in global business expansion. Reflecting on the company’s journey, Jadhav highlighted Dubai’s conducive environment for entrepreneurship, citing it as a catalyst for SAVA HEALTHCARE’s exponential growth since its establishment in 2007. The event’s theme, “Connect with Opportunities to Progress,” resonated with the attendees, showcasing the CEPA’s potential in fostering bilateral trade and collaboration.
Pharmaceutical Prowess:
SAVA Healthcare’s subsidiary, SAVAVET, has emerged as a frontrunner in the small animal pharmaceutical sector, securing a dominant position in the Indian market. From humble beginnings as a Pune-based merchant exporter, SAVA Healthcare has expanded its operations to six countries and exports to over 35 nations, exemplifying the power of strategic business decisions and global reach.
Global Reach:
Headquartered in India, SAVA Healthcare operates a Health Canada and PIC/s certified manufacturing facility in Gujarat, coupled with a state-of-the-art R&D center in Pune. The company’s International Business division extends its reach across North America, Central America, Asia, Africa, and the CIS countries, distributing both human and veterinary pharmaceuticals. Renowned for its expertise in Nasal Drug Delivery Platforms, SAVA’s Contract Research & Manufacturing Services (CRAMS) division serves as a reliable partner for a diverse clientele, positioning the company as a prominent player in the pharmaceutical landscape.
MAHABIZ 2024 not only facilitated dialogue on sustainable development and economic collaboration but also heralded a new era of partnership between India and the UAE. With SAVA Healthcare’s pioneering efforts in pharmaceuticals and its commitment to innovation, the company continues to shape the global healthcare landscape, epitomizing the spirit of collaboration and progress.